{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:47:09Z","timestamp":1762634829902,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019533","name":"Moderna Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jvacx.2025.100678","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:21:48Z","timestamp":1750332108000},"page":"100678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Christopher W.","family":"Dukes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianxing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Cubitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Leav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Rathwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Pilon-Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jvacx.2025.100678_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without Cancer","volume":"8","author":"Chavez-MacGregor","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jvacx.2025.100678_bb0010","article-title":"Role of COVID-19 vaccines in SARS-CoV-2 variants","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2025.100678_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109968","article-title":"Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2","volume":"117","author":"Firouzabadi","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"39","key":"10.1016\/j.jvacx.2025.100678_bb0020","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.39.2100894","article-title":"Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to august 2021","volume":"26","author":"Mart\u00ednez-Baz","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jvacx.2025.100678_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068848","article-title":"Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study","volume":"375","author":"Bruxvoort","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.jvacx.2025.100678_bb0030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/cid\/ciac290","article-title":"Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada","volume":"75","author":"Skowronski","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2025.100678_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jvacx.2025.100678_bb0040","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMc2113864","article-title":"BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant","volume":"385","author":"Sheikh","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jvacx.2025.100678_bb0045","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 vaccination on transmission of alpha and Delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jvacx.2025.100678_bb0050","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2025.100678_bb0055","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jvacx.2025.100678_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947187","article-title":"SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged \u226460 years: one year of surveillance","volume":"13","author":"Franzese","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2025.100678_bb0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s43856-022-00151-2","article-title":"Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders","volume":"2","author":"Lake","year":"2022","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.jvacx.2025.100678_bb0070","article-title":"A third dose of an inactivated vaccine dramatically increased the levels and decay times of anti-SARS-CoV-2 antibodies, but disappointingly declined again: a prospective, longitudinal, cohort study at 18 serial time points over 368 days","volume":"13","author":"Liang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jvacx.2025.100678_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/vaccines12010013","article-title":"Neutralizing antibody response following a third dose of the mRNA-1273 vaccine among cancer patients","volume":"12","author":"Dukes","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.jvacx.2025.100678_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/v14071560","article-title":"Overview of neutralization assays and international standard for detecting SARS-CoV-2 neutralizing antibody","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2025.100678_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1181991","article-title":"Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform","volume":"14","author":"Patil","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2025.100678_bb0090","unstructured":"Meso Scale Discovery. MSD MULTI-SPOT assay System: COVID-19 ACE2 neutralization kits. 2024. Meso Scale Diagnostics."},{"issue":"3","key":"10.1016\/j.jvacx.2025.100678_bb0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/trf.16823","article-title":"Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants","volume":"62","author":"Di Germanio","year":"2022","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.jvacx.2025.100678_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24184","article-title":"Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021","volume":"10","author":"Greene","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.jvacx.2025.100678_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01315-22","article-title":"Correlation of SARS-CoV-2 viral neutralizing antibody titers with anti-spike antibodies and ACE-2 inhibition among vaccinated individuals","volume":"10","author":"Grunau","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"7","key":"10.1016\/j.jvacx.2025.100678_bb0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cac2.12453","article-title":"Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients","volume":"43","author":"Giuliano","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.jvacx.2025.100678_bb0115","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamaoncol.2022.0001","article-title":"Evaluation of antibody response to SARS-CoV-2 mRNA-1273 vaccination in patients with cancer in Florida","volume":"8","author":"Giuliano","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jvacx.2025.100678_bb0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ejh.13986","article-title":"Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies","volume":"111","author":"Heftdal","year":"2023","journal-title":"Eur J Haematol"},{"year":"2024","series-title":"V-PLEX SARS-CoV-2 Panel 11 (ACE2) Kit","author":"Meso Scale Discovery","key":"10.1016\/j.jvacx.2025.100678_bb0125"},{"author":"Katella","key":"10.1016\/j.jvacx.2025.100678_bb0130"},{"issue":"27","key":"10.1016\/j.jvacx.2025.100678_bb0135","doi-asserted-by":"crossref","first-page":"E1059","DOI":"10.1503\/cmaj.1095949","article-title":"Alpha, Beta, Delta, gamma: what's important to know about SARS-CoV-2 variants of concern?","volume":"193","author":"Duong","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.jvacx.2025.100678_bb0140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cytogfr.2023.11.004","article-title":"The impact of COVID-19 on cancer patients","volume":"75","author":"Wekking","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"year":"2024","series-title":"Comparing the COVID-19 vaccines: how are they different?","author":"Katella","key":"10.1016\/j.jvacx.2025.100678_bb0145"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136225000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136225000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:43:11Z","timestamp":1762634591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136225000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"alternative-id":["S2590136225000725"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2025.100678","relation":{},"ISSN":["2590-1362"],"issn-type":[{"type":"print","value":"2590-1362"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2025.100678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100678"}}